These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

278 related items for PubMed ID: 21715364

  • 21. S-1 (Teysuno) and gemcitabine in Caucasian patients with unresectable pancreatic adenocarcinoma.
    Winther SB, Bjerregaard JK, Schonnemann KR, Ejlsmark MW, Krogh M, Jensen HA, Pfeiffer P.
    Cancer Chemother Pharmacol; 2018 Mar; 81(3):573-578. PubMed ID: 29387963
    [Abstract] [Full Text] [Related]

  • 22. Retrospective study of gemcitabine plus S-1 versus gemcitabine alone in cases with unresectable advanced pancreatic cancer.
    Suzuki S, Ozaki Y, Saida S, Kaji S, Koike N, Harada N, Hayashi T, Suzuki M.
    Hepatogastroenterology; 2013 Jun; 60(124):916-20. PubMed ID: 23478143
    [Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31. Randomized phase II trial of S-1 and cisplatin versus gemcitabine and cisplatin in patients with advanced biliary tract adenocarcinoma.
    Kang MJ, Lee JL, Kim TW, Lee SS, Ahn S, Park DH, Lee SS, Seo DW, Lee SK, Kim MH.
    Acta Oncol; 2012 Sep; 51(7):860-6. PubMed ID: 22559158
    [Abstract] [Full Text] [Related]

  • 32. Phase I clinical trial of oral administration of S-1 in combination with intravenous gemcitabine and cisplatin in patients with advanced biliary tract cancer.
    Shoji H, Morizane C, Sakamoto Y, Kondo S, Ueno H, Takahashi H, Ohno I, Shimizu S, Mitsunaga S, Ikeda M, Okusaka T.
    Jpn J Clin Oncol; 2016 Feb; 46(2):132-7. PubMed ID: 26685318
    [Abstract] [Full Text] [Related]

  • 33. A multicenter phase II trial of S-1 with concurrent radiation therapy for locally advanced pancreatic cancer.
    Ikeda M, Ioka T, Ito Y, Yonemoto N, Nagase M, Yamao K, Miyakawa H, Ishii H, Furuse J, Sato K, Sato T, Okusaka T.
    Int J Radiat Oncol Biol Phys; 2013 Jan 01; 85(1):163-9. PubMed ID: 22677367
    [Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35. A Multicenter Phase II Study of Gemcitabine plus S-1 Chemotherapy for Advanced Biliary Tract Cancer.
    Arima S, Shimizu K, Okamoto T, Toki M, Suzuki Y, Okano N, Naruge D, Kawai K, Kobayashi T, Kasuga A, Kitamura H, Takasu A, Nagashima F, Sugiyama M, Furuse J.
    Anticancer Res; 2017 Feb 01; 37(2):909-914. PubMed ID: 28179351
    [Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37. Fixed dose rate infusion of gemcitabine with oral doxifluridine and leucovorin for advanced unresectable pancreatic cancer: a phase II study.
    Kim H, Park JH, Shin SJ, Kim MJ, Bang SJ, Park NH, Nah YW, Nam CW, Joo KR, Min YJ.
    Chemotherapy; 2008 Feb 01; 54(1):54-62. PubMed ID: 18073472
    [Abstract] [Full Text] [Related]

  • 38. Unexpected Side Effects of a High S-1 Dose: Subanalysis of a Phase III Trial Comparing Gemcitabine, S-1 and Combinatorial Treatments for Advanced Pancreatic Cancer.
    Kobayashi S, Ueno M, Hara H, Irie K, Goda Y, Moriya S, Tezuka S, Tanaka M, Okusaka T, Ohkawa S, Morimoto M.
    Oncology; 2016 Feb 01; 91(3):117-26. PubMed ID: 27303788
    [Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 14.